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Angiogenesis is defined as the formation of new blood
vessels from preexisting vasculature. Preclinical studies
have shown the major role of angiogenesis in tumor growth
and metastasis formation, and therefore, inhibiting tumor
angiogenesis may be a promising therapeutic modality [1,
2]. Paracrine stimuli derived from tumor cells are the main
promoters of angiogenesis. Once activated by these stimuli,
endothelial cells begin to proliferate and migrate, subse-
quently resulting in new tube formation and blood flow.
This complex process involves numerous biological activi-
ties. Vascular endothelial growth factor (VEGF) is one of
the most potent and specific angiogenic factors of tumor-
induced angiogenesis [3, 4]. Originally identified for its
ability to induce vascular permeability and stimulate
endothelial cell growth, VEGF is now recognized as a key
factor required for growth of tumors [5]. The clinical
importance of VEGF for tumor growth is supported by the
fact that most tumors produce VEGF and that inhibition of
VEGF-induced angiogenesis significantly inhibits tumor
growth in vivo [6-8]. In addition to decreasing the number
of vessels, antiangiogenic drugs may also decrease the
interstitial tumor pressure. This reduction in interstitial
pressure may result from the ability of these agents to block
VEGF-induced permeability. VEGF expression has been
shown to correlate with microvessel density in a number of
solid malignancies including carcinomas of the breast, and
tissue concentrations of this growth factor appear to be pre-
dictive of mortality associated with breast cancer [9, 10].
Similar results have been obtained in studies of solid malig-
nancies in various organs including the lung, prostate, and
colon [11-13]. These preclinical and clinical findings sup-
port VEGF as a promising target for anticancer therapy.
In patients with cancer, antiangiogenic agents, used
alone or combined with chemotherapy, may inhibit tumor
growth, reduce metastasis formation, prolong survival, and
improve quality of life. Clinicians need to make a major
shift in their thinking if the beneficial effects of these novel
agents are to be recognized. Appropriate schedules of such
combinations need to be developed so that the mechanism
of action (i.e., antiangiogenic or cytotoxic) is fully consid-
ered. The concern that concomitant administration of
antiangiogenic drugs and chemotherapy will impair cyto-
toxic drug delivery is precluded by evidence from animal
studies. Teicher et al. [14-16] clearly demonstrated that
combination therapy with angiogenesis inhibitors has syn-
ergistic antitumor effects in the Lewis lung carcinoma
xenograft model. In these studies, addition of the antiangio-
genic agents to the cytotoxic therapies reduced not only the
number of lung metastases formed from the primary tumor
but also the number of large metastases. These results pro-
vide evidence that antiangiogenic therapies can potentiate
the efficacy of standard anticancer therapies.
This special issue of The Oncologist presents a diversity
of preclinical and clinical studies about anti-VEGF strategies
for cancer treatment. McMahon gives an excellent overview
of the role of VEGF tyrosine kinase receptors in tumor angio-
genesis and the strategies being developed to inhibit this sig-
naling pathway. Subsequently, Ellis presents preclinical data
that show the role of VEGF in the growth and metastasis of
colon cancer. He also presents evidence that antiangiogenic
therapy with VEGF receptor inhibitors SU5416 and SU6668
inhibits the growth of liver metastases. The study by Vajkoczy
and coworkers strongly supports the idea that regional differ-
ences in Flk-1 activity in vivo may significantly affect tumor
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susceptibility to compounds that target the VEGF-Flk-1/KDR.
Their study evaluated regional VEGF-Flk-1/KDR activities in
vivo using SU5416 as measured by intravital fluorescence
videomicroscopy. Rosen presents an overview of clinical stud-
ies of antiangiogenic therapy. Arastéh and Hannah review evi-
dence that anti-VEGF treatment might also benefit patients
with AIDS-related Kaposi’s sarcoma. This is followed by an
overview by Harris on the role of the von Hippel-Lindau
(VHL) tumor-suppressor gene in regulating VEGF expression
and the rationale for the use of SU5416 treatment in VHL
patients. Gasparini reviews the importance of VEGF tissue
levels in treatment planning for breast cancer. Another
promising application for anti-VEGF treatment is presented
by Verheul and coworkers, who propose SU5416 as a treat-
ment for ascites and pleural effusion formation in patients with
advanced-stage cancer. Finally, Carter addresses the chal-
lenging question of the selection of strategies for clinical
development of angiogenesis inhibitors.
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